TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in isometric quadriceps muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of subjects with specific Long Term Follow-Up adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Dose-Limiting Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Vasopressor dependency index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steps Walked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average proportion of days of any app use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average proportion of days of PrEP medication tracked
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean intervention acceptability, composite score CSQ-8
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative overall complications
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of vomiting, retching or nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Effect of CPAP on sleep apnea symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective rate of response (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postvoiding residual urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clean intermittent catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean reduction in ODD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Margin positivity after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Panic Disorder Severity Scale (PDSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hamilton Depression Rating Scale (HDRS), 28 Item Version
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Progression of Carotid Intima Media Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gut microbiome alpha diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faecal short chain fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage Change of Tumor Cells Exhibiting Detectable Staining Within Gleason Grade 3 (GG3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage Change of Tumor Cells Exhibiting Detectable Staining Within Gleason Grade 4 (GG4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Difference in mitochondrial number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in exercise performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hazard Ratio for Hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Change in the result of Chinese Handwriting Evaluation Form
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the total point score of three subtests of Bruininks-Oseretsky Test of Motor Proficiency, Second Edition (BOT-2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the handwriting kinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the handwriting kinematic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Re-randomization Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Height in meters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waist circumference in centimeters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of treatment-related grade 3-5 toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: T50 CIT values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammation & oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Trastuzumab-Induced Cardiotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With LVEF Decrease to <50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Invasive Disease-Free Survival (iDFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change in muscle dialysate lactate-pyruvate ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lichen Planopilaris index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of the lesion in the lateral canals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of lateral canal filled
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area of the lateral canal filled
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of diabetic foot ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of foot infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of Charcot fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Breath Volatile Organic Compound Profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proliferation and survival of mast cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of non-widespread skin lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of girths in both thighs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of fat amounts in both thighs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed Occurrence of Major Adverse Cardiovascular Event (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients responding to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periodontal health knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Natriuretic response to intravascular volume expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Natriuretic response to IV diuretic administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma selenium biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Radiological classification of vertical segment of facial nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Depth of Necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: G-STAT questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Predictive ability of the MiCK assay for chemotherapy outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Brief Pain Inventory (BPI) at Week 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Algometer-induced Pressure Pain at Week 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weighted Pinprick Stimulator-induced Mechanical Pain at Week 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ice Water-induced Cold Pain and Its After-sensation at Week 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence-free survival at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of 14C-lazertinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Observed Plasma Concentration (Tmax) of 14C-lazertinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUC [0-infinity]) of 14C-lazertinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stimulated serum cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sustained Virologic Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Pain Visual Analogue Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Fetal ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Size change of the fenestration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of swallowability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: insertional torque value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ADAS-Cog scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: systemic exposure to tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in visceral fat area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in body fat ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite of fatal and non-fatal stroke
Endpoint domain: Mortality/survival
Primary endpoint: Fear extinction measured by Skin conductance response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear extinction measured by Fear-potentiated startle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Montreal Cognitive Assessment (MoCA) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Dual task gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dual task standing postural sway area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical or clinical progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in the incidence of vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in the cardinal symptoms of motion sickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of vomiting and retching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of plasma total homocysteine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of SpO2 <90% during seizure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent of Participants With DMPA Concentrations Below 0.1 ng/mL at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percent of Participants With Progesterone Levels Above 1 ng/mL at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in the number of serodiscordant condomless anal sex acts
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Percent Change in Number of TSC-Associated Seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: self-reported 7-day point prevalence quit rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: prolonged abstinence quit rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rhinoconjunctivitis Symptom-Medication-Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraoperative incidence of hypothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Release of satiety hormones (CCK, PYY, GLP-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Dose Related Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Recurrent or New Symptomatic Venous Thromboembolism (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Postoperative Cognitive Decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Epidemiology of Diamond Blackfan anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biology of Diamond Blackfan anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCC
Endpoint domain: Mortality/survival
Primary endpoint: Decompensated cirrhosis
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With a Hemoglobin (Hb) Response to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hb Change From Baseline (BL) to the Average Hb in Weeks 28-52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Recurrence of syncope or presyncope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of durable posterolateral fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Plaque Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Change in Gingival Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Residual tumor at the end of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Anterior-posterior Spine Bone Mass Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Spine Bone Mineral Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in parental knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Degree of surgical resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Psychological development
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: deft/DMFT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Matsuda Index of Whole-Body Insulin Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: β-cell Insulin Secretion Capacity Assessed by the Insulinogenic Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pharmacokinetics of bilastine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality of acute pancreatitis
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy of DBS for measuring drug levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postmenstrual age at the time of full oral feedings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postmenstrual age at the time of hospital discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of CTS symptoms intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Scar Assessment Score (OSAS) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of early preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Changes in liver function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Clinical significant changes in cerebral activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical significant changes in QTcF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Number of Micturitions Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Gastro-intestinal Issues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: modified Ranking Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in integrated mineral loss from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricle ejection fraction change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Attitude Scale Towards Distance Education
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Renin activity and concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the concentration-time curve of aciclovir in plasma (AUC0-12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured concentration of aciclovir in plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed drug concentration of ethinylestradiol at steady state after multiple administrations of Microgynon (Cmax)ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed drug concentration of ethinylestradiol after single administration of Noristerat (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve of ethinylestradiol after single administration of Noristerat (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin elasticity measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in general self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Presence of bone erosions and structural lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With One or More Clinically Significant Event(s)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Diurnal IOP (Intraocular Pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Diseases morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in retention of complete denture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety following vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported contraceptive use
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Percentage of app based EPDS assessments completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Usability of the headset
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cognitive load assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Normalization Rate of CA 19-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose of Dacomitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of the combination of Dacomitinib, Cisplatin and Radiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enrollment in new community-based resources and services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Elastography data of adenomyotic lesions and fibroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Children's Depression Inventory 2 - Youth Report Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Hemoglobin A1c (A1c) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inattentive Subscale score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in PWT on graded treadmill test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of cryoablation with systemic atezolizumab/nab-paclitaxel
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of cryoablation with systemic atezolizumab/nab-paclitaxel
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of erectile function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival to Discharge
Endpoint domain: Mortality/survival
Primary endpoint: Safety Analysis of Bleeding Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Patients ability to successfully use the PaQ™ device
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Confirmed Response
Endpoint domain: Mortality/survival
Primary endpoint: CD 8+ CD 57+ CD 28- / CD 8+ T lymphocytes Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes